Ben Watt Joins SERB and BTG as Group CFO

LONDON – 21 October 2021 – SERB and BTG Specialty Pharmaceuticals are pleased to announce that Ben Watt has been named the group’s new Chief Financial Officer. Ben is an experienced CFO with a track record of building global finance teams and integrating business acquisitions.

Ben most recently served as CFO of Crouzet, an independent manufacturer of electronic components used in heavily regulated industries. He previously worked as a Director at Eight Advisory, a Paris-based advisory firm focused on due diligence for leveraged buyout funds and large corporations, with extensive exposure to the US and international markets. He started his career in audit and due diligence at Arthur Andersen.

Anthony Higham, who was appointed CEO of the group in September 2021, said: “Ben is a highly skilled practitioner, adept at complex business integrations, building high-performing teams, and working with private equity backers. We are confident that he will deliver the broad strategic perspective and rigorous attention to detail needed to accomplish our goals.”

Ben graduated with a First-Class degree in Law from the University of Edinburgh. He spent an exchange year at Université de Poitiers in France and is fluent in French. He received a CA (CPA equivalent) from the Institute of Chartered Accountants of Scotland.

SERB acquired BTG Specialty Pharmaceuticals in March 2021. SERB is a pan-European specialty pharmaceutical group providing a reliable supply of prescription medicines to patient suffering from rare and life-threatening diseases. BTG develops, manufactures, and commercializes antidotes that counteract the potentially life-threatening effects associated with exposure to certain toxins. Together, SERB and BTG are a fully integrated, global specialty pharmaceutical platform and a dedicated ally to healthcare providers treating patients with critical conditions.

Backed by Charterhouse Capital Partners LLP, Partners Group, and Merieux Equity Partners, the firm has more than 400 employees in 11 offices, advanced manufacturing facilities, and a direct commercial presence in all major pharmaceutical markets worldwide.

About SERB and BTG Specialty Pharmaceuticals

Together, SERB and BTG are a growing specialty pharmaceutical platform and a dedicated ally to healthcare providers treating patients with critical conditions, focusing on emergency care and rare diseases. For over 30 years we have made treating these complex and life-threatening conditions possible, supporting clinicians, healthcare systems and governments while offering hope to patients and their families. As a fully integrated company, we have the experience and capabilities to acquire, develop, and manufacture our medicines to the highest standards, and make them available worldwide through our secure supply chain.

Learn more about SERB:
Learn more about BTG Specialty Pharmaceuticals:

For further information contact:
Chris Sampson, Corporate Communications Director; Mobile: +44 (0)7773 251 178

Back to news
You are leaving the global corporate website
This link will take you to a third-party website, the terms of use and the privacy policy of which may be different. SERB declines all responsibility in that regard and in case of a breach of its privacy policy by the third-party website. Moreover, SERB is not responsible for any information or opinion contained in any third-party website.
Choose your region